What is a stock summary page? Click here for an overview.
Business Description
Fortress Biotech Inc
NAICS : 325412
SIC : 2834
ISIN : US34960Q1094
Description
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.75 | |||||
| Equity-to-Asset | 0.16 | |||||
| Debt-to-Equity | 3.34 | |||||
| Debt-to-EBITDA | -0.74 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -8.93 | |||||
| Beneish M-Score | -1.48 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -39.7 | |||||
| 3-Year EBITDA Growth Rate | 42.8 | |||||
| 3-Year FCF Growth Rate | 42.7 | |||||
| 3-Year Book Growth Rate | -62.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 43.88 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 52.55 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.94 | |||||
| 9-Day RSI | 61.09 | |||||
| 14-Day RSI | 55.65 | |||||
| 3-1 Month Momentum % | -3.85 | |||||
| 6-1 Month Momentum % | -5.41 | |||||
| 12-1 Month Momentum % | 1.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.27 | |||||
| Quick Ratio | 1.06 | |||||
| Cash Ratio | 0.8 | |||||
| Days Inventory | 198.21 | |||||
| Days Sales Outstanding | 71.37 | |||||
| Days Payable | 630.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -59.8 | |||||
| Shareholder Yield % | -151.54 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.8 | |||||
| Operating Margin % | -192.71 | |||||
| Net Margin % | -79.75 | |||||
| FCF Margin % | -139.04 | |||||
| ROE % | -214.26 | |||||
| ROA % | -30.7 | |||||
| ROIC % | -193.02 | |||||
| 3-Year ROIIC % | -4941.2 | |||||
| ROC (Joel Greenblatt) % | -550.19 | |||||
| ROCE % | -151.49 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.11 | |||||
| PB Ratio | 1.99 | |||||
| EV-to-EBIT | -0.39 | |||||
| EV-to-Forward-EBIT | -1.43 | |||||
| EV-to-EBITDA | -0.41 | |||||
| EV-to-Forward-EBITDA | -1.43 | |||||
| EV-to-Revenue | 0.74 | |||||
| EV-to-Forward-Revenue | 0.92 | |||||
| EV-to-FCF | -0.53 | |||||
| Price-to-GF-Value | 0.24 | |||||
| Earnings Yield (Greenblatt) % | -256.41 | |||||
| FCF Yield % | -165.56 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FBIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fortress Biotech Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 57.675 | ||
| EPS (TTM) ($) | -13 | ||
| Beta | 1.39 | ||
| 3-Year Sharpe Ratio | -0.76 | ||
| 3-Year Sortino Ratio | -0.95 | ||
| Volatility % | 59.14 | ||
| 14-Day RSI | 55.65 | ||
| 14-Day ATR ($) | 0.110607 | ||
| 20-Day SMA ($) | 1.5305 | ||
| 12-1 Month Momentum % | 1.74 | ||
| 52-Week Range ($) | 1.325 - 2.89 | ||
| Shares Outstanding (Mil) | 29.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fortress Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fortress Biotech Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Fortress Biotech Inc Frequently Asked Questions
What is Fortress Biotech Inc(FBIO)'s stock price today?
The current price of FBIO is $1.64. The 52 week high of FBIO is $2.89 and 52 week low is $1.33.
When is next earnings date of Fortress Biotech Inc(FBIO)?
The next earnings date of Fortress Biotech Inc(FBIO) is 2025-05-15 Est..
Does Fortress Biotech Inc(FBIO) pay dividends? If so, how much?
Fortress Biotech Inc(FBIO) does not pay dividend.
Guru Commentaries on NAS:FBIO
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers